Over the next five years, pharma giant, AstraZeneca will invest $90 million in India to improve the overall health outcomes in the country, by promoting innovation, skill development, and quality manufacturing.
Big pharma players including Novartis, Roche, Pfizer, Sanofi are embracing digital technologies to deliver better to the patients.
FDA’S 2018 Strategic Policy Roadmap indicates increasing number of digital health clearances in coming times with revised regulatory processes.
The artificial intelligence (AI) based device called IDx-DR received US FDA approval for the screening of diabetic retinopathy- a common eye disease in diabetic patients that could lead to vision impairment and blindness.
Novartis bets high by acquiring the non-earning US-based gene therapy firm AveXis for $8.7 billion. But, AveXis' novel gene therapy- AVXS-101 could be a “game-changing” treatment for SMA patients and could turn out to be a potential blockbuster for Novartis, if approved.